Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
123完成签到,获得积分10
刚刚
刚刚
刚刚
优秀的半凡完成签到,获得积分10
1秒前
rui完成签到,获得积分10
1秒前
夜夜夜发布了新的文献求助10
1秒前
1秒前
孤独的巨人完成签到,获得积分10
2秒前
3秒前
3秒前
4秒前
4秒前
4秒前
4秒前
Hotdog发布了新的文献求助30
4秒前
慕青应助rrrr采纳,获得10
4秒前
虾哥完成签到,获得积分10
5秒前
科研通AI6.2应助Charlie采纳,获得10
5秒前
Di发布了新的文献求助10
6秒前
lore完成签到,获得积分10
6秒前
7秒前
7秒前
忧郁平文完成签到,获得积分10
7秒前
8秒前
8秒前
隐形访文发布了新的文献求助10
8秒前
凡尘浮生发布了新的文献求助10
8秒前
8秒前
科研彭于晏完成签到,获得积分10
8秒前
Owen应助A拉拉拉采纳,获得10
9秒前
甜蜜屁池完成签到,获得积分10
9秒前
YMUSTC完成签到,获得积分10
9秒前
合适忆灵发布了新的文献求助10
10秒前
Jasper应助mwkslwg采纳,获得10
10秒前
至幸完成签到,获得积分10
11秒前
yk应助迷人的石头采纳,获得10
11秒前
小蘑菇应助吴念采纳,获得10
12秒前
叶凡应助健康的雁凡采纳,获得10
12秒前
光亮续发布了新的文献求助10
12秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Cronologia da história de Macau 5000
咳嗽・喀痰の診療ガイドライン第2版2025 800
Petrology and Plate Tectonics 800
Electrode Potentials 550
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
The globalisation of real estate: the politics and practice of foreign real estate investment 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7011729
求助须知:如何正确求助?哪些是违规求助? 8685417
关于积分的说明 18411189
捐赠科研通 6497930
什么是DOI,文献DOI怎么找? 3105242
关于科研通互助平台的介绍 2174953
邀请新用户注册赠送积分活动 2081398